Anti-Human FOLR1 (folate receptor 1) (Mirvetuximab) - 100 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Folate receptor 1 (FOLR1), also known as folate receptor alpha (FRα), is aglycosylphosphatidylinositol-anchored glycoprotein essential for transporting folate into cells.Elevated FOLR1 levels are linked to poor prognosis in cancers such as breast cancer andendometrial carcinoma, making it a potential target for cancer therapy. It has also beeninvestigated as a biomarker for cancer diagnosis and a target for delivering cytotoxic agents, particularly in cancers affecting women1, 2. Mirvetuximab (M9346A) is an antibody-drug conjugate that targets folate receptor alpha(FRα), commonly overexpressed in cancers such as ovarian cancer. The initial phase IIIFORWARD I trial did not show significant benefits in FRα-positive tumors. However, subsequent studies focusing on patients with high FRα expression produced promisingresults. Consequently, the US FDA granted accelerated approval for Mirvetuximab inpatients with FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritonealcancer. Mirvetuximab has demonstrated efficacy in reducing the risk of tumor progression ordeath compared to chemotherapy, providing a valuable treatment option for advanced orrecurrent ovarian cancer3. This research-grade biosimilar does not contain the drug conjugate.

≥ 5.0 mg/ml

While normally expressed on the apical surfaces of healthy epithelialtissues, FOLR1 is overexpressed in various solid tumors, including ovarian, breast, lung, andgastric cancers.